9 En anden farmakodynamisk markør, forenelig med efalizumabs virkningsmekanisme, var en stigning i det absolutte cirkulerende leukocyttal observeret i løbet af behandlingen med efalizumab.
Another pharmacodynamic marker, consistent with the mechanism of action of efalizumab, was the increase in the absolute counts of circulating leukocytes observed during efalizumab treatment.